<DOC>
	<DOCNO>NCT02683395</DOCNO>
	<brief_summary>The purpose research study evaluate safety , pharmacokinetics , pharmacodynamics , preliminary efficacy investigational drug PLX51107 subject advanced solid tumor ( include lymphoma ) , acute myeloid leukemia ( AML ) , high-risk myelodysplastic syndrome ( MDS ) .</brief_summary>
	<brief_title>A Study PLX51107 Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Confirmed diagnosis advance malignancy one two treatment group : Treatment Group A : advanced solid tumor ( include lymphoma ) ; Treatment Group B : relapsed refractory AML highrisk MDS , define IPSS INT2 great disease ( Maes 1999 ) . Progressed follow least 1 line prior anticancer therapy advance disease standard therapeutic option available ( include subject intolerant approved/available therapy ) Age ≥ 18 year Eastern Cooperative Oncology Group ( ECOG ) performance Status ( PS ) 02 Life expectancy ≥ 3 month Adequate organ function demonstrate follow laboratory value ( collect within 10 day treatment initiation ) appropriate disease study . Women childbearing potential must negative serum pregnancy test Screening must agree use effective form contraception time negative pregnancy test 6 month last dose study drug . Women nonchildbearing potential may include either surgically sterile postmenopausal ≥ 1 year . Fertile men must agree use effective method birth control study 6 month last dose study drug All associate toxicity , except grade 2 alopecia , previous cancer therapy must resolve ( ≤ Grade 1 Baseline ) prior study treatment administration ( Grade 2 alopecia allow ) . Willingness ability provide write informed consent prior studyrelated procedure comply study requirement . Prior exposure bromodomain inhibitor Active graft versus host disease Known uncontrolled fungal , bacterial , and/or viral infection ≥ Grade 2 Uncontrolled autoimmune hemolytic anemia thrombocytopenia Presence symptomatic uncontrolled central nervous system leptomeningeal metastasis ( Note : Subjects stable , treated brain metastasis eligible trial . However , subject must require steroid treatment brain metastasis within 30 day Screening . ) A diagnosis acute promyelocytic leukemia ( APL ) chronic myeloid leukemia ( CML ) blast crisis Known suspect allergy investigational agent agent give association trial Clinically significant cardiac arrhythmia include bradyarrhythmias and/or subject require antiarrhythmic therapy ( exclude beta blocker digoxin ) . Subjects control atrial fibrillation exclude . Congenital long QT syndrome subject take concomitant medication know prolong QT interval except treatment require infection low risk QTc prolongation . Subjects active anticoagulation therapy include warfarin , factor Xa inhibitor , thrombin inhibitor heparin QTcF ≥ 450 msec ( male ) ≥ 470 msec ( female ) Screening History clinically significant cardiac disease congestive heart failure &gt; New York Heart Association ( NYHA ) class 2 . Subjects must unstable angina ( anginal symptom rest ) newonset angina within last 3 month myocardial infarction within past 6 month . Hypertension define systolic blood pressure &gt; 150 mmHg diastolic blood pressure &gt; 90 mmHg despite optimal medical management Arterial venous thrombotic embolic event cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis , pulmonary embolism within 6 month start study medication ( except adequately treat catheterrelated venous thrombosis occur 1 month start study medication ) Inability take oral medication significant nausea vomiting , malabsorption , significant small bowel resection , opinion Investigator , would preclude adequate absorption Nonhealing wound , ulcer , bone fracture Known HIVpositive individual combination antiretroviral therapy Subjects know active hepatitis B C , chronic hepatitis B C require treatment antiviral therapy Presence psychological , familial , sociological geographical condition potentially hamper compliance study protocol Strong CYP3A4 2C8 inhibitor inducer CYP3A4 substrate drug narrow therapeutic range within 14 day 5 drug halflives , whichever longer , start study drug Subjects &gt; Grade 1 serum potassium , magnesium , calcium level Active secondary malignancy ( either concurrent within last 3 year ) require nonsurgical therapy ( e.g. , chemotherapy radiation therapy ) , exception surgically treat basal squamous cell carcinoma skin , melanoma insitu , carcinoma insitu cervix Major surgery significant traumatic injury within 14 day prior Cycle 1 Day 1 Receipt anticancer medication investigational drug within follow interval first administration study drug : &lt; 14 day 5 drug halflives , whichever short , chemotherapy investigational agent &lt; 5 halflives anticancer medication , Sponsor approval leukopheresis and/or hydroxyurea leukocytosis allow time prior study reduce WBC Radiation therapy within 14 day prior Cycle 1 Day 1 Any medical condition ( ) , opinion Investigator , would interfere study endpoint subject 's ability participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>PLX51107</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Neoplasms</keyword>
</DOC>